HDL--is it too big to fail? (Q46866176)

26 December 2017

review article

1 reference

title

HDL--is it too big to fail? (English)

1 reference

26 December 2017

3

Robert A Hegele

0 references

author name string

Dominic S Ng

series ordinal

1

1 reference

26 December 2017

Norman C W Wong

series ordinal

2

1 reference

26 December 2017

publication date

15 January 2013

1 reference

26 December 2017

Nature Reviews Endocrinology

published in

1 reference

26 December 2017

volume

9

1 reference

26 December 2017

page(s)

308-312

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1038/nrendo.2012.238

exact match

0 references

cites work

Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

HDL-C: role as a risk modifier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

High-density lipoproteins and cardiovascular disease: 2010 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Recombinant high-density lipoprotein formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

High-density lipoproteins, inflammation and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Is raising HDL a futile strategy for atheroprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Update on strategies to increase HDL quantity and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Metabolic and functional relevance of HDL subspecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Anti-inflammatory properties of paraoxonase-1 in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Novel HDL-directed pharmacotherapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

High-density lipoprotein/apolipoprotein A-I infusion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Genetics of cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Rationale for cholesteryl ester transfer protein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Apolipoprotein A-I deficiency. Biochemical and metabolic characteristics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Genetic variant of the scavenger receptor BI in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

Dalcetrapib , a cholesteryl ester transfer protein modulator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.238

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2012.238

1 reference

26 December 2017

PubMed ID

23318230

1 reference

26 December 2017